Beijing, China, December 8, 2022 -  Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087. SH) is pleased to announce its insulin glargine(prefilled pen) has been approved by the Regulatory Authority of Pakistan for the treatment of diabetes. This means that Gan & Lee officially obtained license to sell insulin glargine product to Pakistan. It’s also an important milestone for Gan & Lee as a marketing authorization holder (MAH) for the first time in the Asia-Pacific region.

Located in South Asia, Pakistan has a population of 225 million(2021), as the sixth most populous country in the world. It is one of the three most important economies in the region with a per capita GDP of US$1,537.9(2021, international exchange rate)¹. According to the International Diabetes Federation (IDF) Atlas 10th edition, as of 2021, there are 33 million people(aged 20-79) in Pakistan living with diabetes. The number of patients is the third largest, only after China and India and the prevalence is 30.8%. This prevalence ranks first in the world². With a huge patient base, Pakistan's diabetes market still has huge space and potential for growth. For Pakistan’s insulin market, the total volume exceeds 50 million USD³. Sanofi, Novo Nordisk and Eli Lilly's insulin drugs account for the majority of the country's market share. This approval allows the official entry of Gan & Lee’s products, and introduces anothter high-quality options to Pakistani patients.

The approval of this overseas product consolidates the company's market position in the field of international diabetes treatment and lays a solid foundation for further expansion of the global market. At present, Gan & Lee's products have obtained drug registration certificates in nearly 20 countries around the world, and the speed of internationalization has steadily accelerated. The company is actively deploying a full range of diabetes treatment products around the world, potentially benefiting more patients through high-quality products and services.

References:

1. Pakistan_World Bank https://data.worldbank.org.cn/country/pakistan?view=chart 

2. IDF Diabetes Atlas 10th edition 2021. Available at: https://diabetesatlas.org/atlas/tenth-edition/ 

3. Data from IQVIA database

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.